FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) [2017] FCA 94
File numbers: NSD 763 of 2013
NSD 251 of 2014Judge: NICHOLAS J Date of judgment: 15 February 2017 Catchwords: PATENTS – where suppliers of generic pharmaceutical products found to have threatened to infringe patent – form of injunctive relief – whether injunction should be granted restraining generic suppliers from applying for listing of their products on the Schedule of Pharmaceutical Benefits – whether by applying for such listing suppliers would be offering to sell or otherwise dispose of products – meaning of “exploit” as defined in Schedule 1 of Patents Act 1990 (Cth)
PRACTICE AND PROCEDURE – where patentee obtains injunction against supplier restraining threatened patent infringement – whether order should be made releasing patentee from undertaking as to damages previously given in support of interlocutory injunction
COSTS – operation of r 25.14 of Federal Court Rules 2011 (Cth) – whether order for indemnity costs appropriate – whether supplier’s failure to accept patentee’s offer of compromise was unreasonable
Legislation: Federal Court of Australia Act 1976 (Cth), s 23
Federal Court Rules 2011 (Cth) r 1.35, r 15.10, r 25.14
National Health Act 1953 (Cth) ss 83AF, 85(6), 99AEB, 99AEE, 99AEF, 99AEG, 99AEH
National Health (Pharmaceuticals and Vaccines - Cost Recovery) Regulation (2009) (Cth) regs 2.1, 2.16
Patents Act 1990 (Cth) ss 13, 117
Cases cited: Apotex Pty Ltd v Warner-Lambert Company LLC(No 2) [2016] FCA 1238
Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd (2015) 323 ALR 429
Brooke & Mackenzie Pty Ltd v El-Gra Engineering Pty Ltd (2015) 331 ALR 535
Commonwealth v Sanofi (2015) 237 FCR 483
Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254
Gerber Garment Technology Inc. v Lectra Systems Ltd [1995] RPC 383
Kooee Communications Pty Ltd v Primus Telecommunications Pty Ltd (No 2) [2011] FCAFC 141
Lodestar Anstalt v Campari America LLC (No 2) [2016] FCAFC 118
Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd [2012] FCA 239
Pharmaceutical Society of Great Britain v Boots Cash Chemists (Southern Ltd) [1952] 2 QB 795
Reardon v Morley Food Pty Ltd (1980) 33 ALR 417
Sanofi-Aventis v Apotex (No 4) (2011) 202 FCR 56
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 3) [2011] FCAFC 165
Date of hearing: 17 November 2016 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and Associated Statutes Category: Catchwords Number of paragraphs: 58
Counsel for the Applicant/Cross-Respondent in NSD 763 of 2013:
Mr NR Murray and Mr MB Fleming Solicitor for the Applicant/Cross-Respondent in NSD 763 of 2013: Ashurst Australia Counsel for the Respondent/Cross-Claimants in NSD 763 of 2013 and Applicants/Cross-Respondents in NSD 251 of 2014: Mr AJL Bannon SC with Mr BA Mee Solicitor for the Respondent/Cross-Claimants in NSD 763 of 2013 and Applicants/Cross-Respondents in NSD 251 of 2014: Allens Linklaters Counsel for the Respondent/Cross-Claimant in NSD 251 of 2014: Ms AH Bowne SC Solicitor for the Respondent/Cross-Claimant…
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2017] FCA 94
- Decision Date
CaseChat Overview and Summary
The court addressed the issue of the form of injunctive relief, focusing on whether the generic suppliers' actions in applying for listing of their products on the Pharmaceutical Benefits Scheme would constitute an offer to sell or otherwise dispose of products, thus triggering patent infringement. The court found that the application for listing did not equate to an offer to sell or dispose of the products, and thus, did not infringe the patent. Consequently, the court granted the permanent injunction restraining the generic suppliers from infringing the patent but clarified that this did not prevent them from taking necessary steps to list their products under the pharmaceutical benefits scheme. The court also discharged previous orders related to damages and released the patentee from the previously given undertaking.
In addition to the injunction, the court ordered that the generic suppliers pay the patentee's costs of the proceeding, excluding any costs subject to previous orders. This decision was based on the generic suppliers' unreasonable refusal to accept a compromise offer from the patentee. The court emphasized the importance of considering offers of compromise in the context of indemnity costs under the Federal Court Rules.
The final orders included dismissing the cross-claim, certifying the questioning of patent validity, discharging certain previous orders, releasing the patentee from the undertaking as to damages, imposing a permanent injunction, and ordering the generic suppliers to pay the patentee's costs of the proceeding. These orders reflect the court's consideration of the specific statutory provisions and the procedural aspects of the case.
Orders
Orders of the court
1. The Cross-Claimant’s Notice of Cross-Claim dated 6 May 2014 be dismissed.
2. A certificate be issued pursuant to section 19 of the Patents Act 1990 (Cth) to certify that the validity of each of claims 1 to 30 of Australian Patent No. 714980 (“the Patent”) was questioned in this proceeding.
3. Order 1 of the orders of Yates J dated 7 April 2014 and order 2 of the orders of Nicholas J dated 23 May 2014 be discharged.
4. The applicants be released from undertaking (c) given to Yates J on 7 April 2014 as set out in Honour’s orders of that date and undertaking (c) given to Nicholas J on 23 May 2014 as set out in his Honour’s orders of that date.
5. The Respondent/Cross-Claimant, whether by itself, its directors, officers, servants or agents or otherwise, be restrained from, in the patent area (as defined in Schedule 1 to the Patents Act 1990 (Cth)) (“the patent area”), during the term of the Patent, and without the licence or authority of the Applicants/Cross-Respondents: – infringing any of claims 1 to 30 inclusive of the Patent, including, in particular, by importing, making, selling, supplying or otherwise disposing of, or offering to import, make, sell, supply or otherwise dispose of, or using or keeping in the patent area, for the purpose of doing any of the foregoing acts, any product containing pregabalin, including, without limitation, any of the products listed in Annexure A to these orders (collectively, the Generic Partners Generic Pregabalin Products), other than as permitted by section 119A or 119C of the Patents Act 1990 (Cth).
6. For the avoidance of doubt, the terms of the injunction imposed by order 5 do not prevent the Respondent/Cross-Claimant from taking any steps required to obtain listing of the Generic Partners Generic Pregabalin Products under the pharmaceutical benefits scheme (“PBS”) maintained under the National Health Act 1953 (Cth).
7. Within 2 days of the date of these orders, the Respondent/Cross-Claimant must notify the Australian Government Department of Health of the granting of the permanent injunction in order 5 and of its terms.
8. The Applicants’ Originating Application dated 7 March 2014 be otherwise dismissed.
9. The Respondent/Cross-Claimant pay the Applicants’/Cross-Respondents’ costs of the proceeding, including any reserved costs, but excluding any costs the subject of any other previous costs order, as agreed or taxed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.